Phosphodiesterase function and endocrine cells: Links to human disease and roles in tumor development and treatment

Current Opinion in Pharmacology

Volumn 11, Issue 6, 2011, Pages 689-697

  Levy, Isaac ^a   Horvath, Anelia ^a   Azevedo, Monalisa ^a   De Alexandre, Rodrigo Bertollo ^a,b   Stratakis, Constantine A ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; CYCLIC AMP; PF 04957325; PHOSPHODIESTERASE; PHOSPHODIESTERASE 11A; PHOSPHODIESTERASE 1B; PHOSPHODIESTERASE 1C; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; PHOSPHODIESTERASE VII; ROLIPRAM; SILDENAFIL; SULINDAC; SULINDAC SULFONE; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL; VINPOCETINE; ZAPRINAST;

ALLERGY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL CYCLE ARREST; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; ENDOCRINE CELL; ENDOCRINE GLAND; EPITHELIAL MESENCHYMAL TRANSITION; ERECTILE DYSFUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; INTERMITTENT CLAUDICATION; METASTASIS; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL;

EID: 82255192267     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2011.10.003     Document Type: Review

References (110)

1. R. Savai, S.S. Pullamsetti, G.A. Banat, N. Weissmann, H.A. Ghofrani, F. Grimminger, and R.T. Schermuly Targeting cancer with phosphodiesterase inhibitors Expert Opin Investig Drugs 19 2010 117 131
2. A. Makhlouf, A. Kshirsagar, and C. Niederberger Phosphodiesterase 11: a brief review of structure, expression and function Int J Impot Res 18 2006 501 509 (Pubitemid 44658541)
3. K. Taskén, B.S. Sklhegg, K.A. Taskén, R. Solberg, H.K. Knutsen, F.O. Levy, M. Sandberg, S. Orstavik, T. Larsen, and A.K. Johansen Structure, function, and regulation of human cAMP-dependent protein kinases Adv Second Messenger Phosphoprotein Res 31 1997 191 204
4. C. Kim, N.H. Xuong, and S.S. Taylor Crystal structure of a complex between the catalytic and regulatory (RIalpha) subunits of PKA Science 307 2005 690 696 (Pubitemid 40194632)
5. C. Kim, C.Y. Cheng, S.A. Saldanha, and S.S. Taylor PKA-I holoenzyme structure reveals a mechanism for cAMP-dependent activation Cell 130 2007 1032 1043 (Pubitemid 47410267)
6. S.H. Francis, and J.D. Corbin Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action Crit Rev Clin Lab Sci 36 1999 275 328 (Pubitemid 29431414)
7. M.J. Kim, J.H. Lee, S.Y. Park, K.W. Hong, C.D. Kim, K.Y. Kim, and W.S. Lee Protection from apoptotic cell death by cilostazol, phosphodiesterase type III inhibitor, via cAMP-dependent protein kinase activation Pharmacol Res 54 2006 261 267 (Pubitemid 44233328)
8. L. Zhang, F. Murray, A. Zahno, J.R. Kanter, D. Chou, R. Suda, M. Fenlon, L. Rassenti, H. Cottam, and T.J. Kipps Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia Proc Natl Acad Sci U S A 105 2008 19532 19537
9. R. Sengupta, T. Sun, N.M. Warrington, and J.B. Rubin Treating brain tumors with PDE4 inhibitors Trends Pharmacol Sci 32 2011 337 344
10. Y.H. Jeon, Y.S. Heo, C.M. Kim, Y.L. Hyun, T.G. Lee, S. Ro, and J.M. Cho Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development Cell Mol Life Sci 62 2005 1198 1220 (Pubitemid 40880125)
11. A.T. Bender, and J.A. Beavo Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use Pharmacol Rev 58 2006 488 520 (Pubitemid 44394910)
12. L.S. Weinstein, A. Shenker, P.V. Gejman, M.J. Merino, E. Friedman, and A.M. Spiegel Activating mutations of the stimulatory G protein in the McCune-Albright syndrome N Engl J Med 325 1991 1688 1695
13. L.S. Kirschner, J.A. Carney, S.D. Pack, S.E. Taymans, C. Giatzakis, Y.S. Cho, Y.S. Cho-Chung, and C.A. Stratakis Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex Nat Genet 26 2000 89 92
14. J.A. Carney, H. Gordon, P.C. Carpenter, B.V. Shenoy, and V.L. Go The complex of myxomas, spotty pigmentation, and endocrine overactivity Medicine (Baltimore) 64 1985 270 283 (Pubitemid 16247109)
15. J. Bertherat, A. Horvath, L. Groussin, S. Grabar, S. Boikos, L. Cazabat, R. Libe, F. Rene-Corail, S. Stergiopoulos, and I. Bourdeau Mutations in regulatory subunit type 1A of cyclic adenosine 5′-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes J Clin Endocrinol Metab 94 2009 2085 2091
16. E.L. Greene, A.D. Horvath, M. Nesterova, C. Giatzakis, I. Bossis, and C.A. Stratakis In vitro functional studies of naturally occurring pathogenic PRKAR1A mutations that are not subject to nonsense mRNA decay Hum Mutat 29 2008 633 639 (Pubitemid 351614587)
17. L. Groussin, L.S. Kirschner, C. Vincent-Dejean, K. Perlemoine, E. Jullian, B. Delemer, S. Zacharieva, D. Pignatelli, J.A. Carney, and J.P. Luton Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD Am J Hum Genet 71 2002 1433 1442 (Pubitemid 36018745)
18. A. Horvath, J. Bertherat, L. Groussin, M. Guillaud-Bataille, K. Tsang, L. Cazabat, R. Libe, E. Remmers, F. Rene-Corail, and F.R. Faucz Mutations and polymorphisms in the gene encoding regulatory subunit type 1-alpha of protein kinase A (PRKAR1A): an update Hum Mutat 31 2010 369 379
19. A. Rothenbuhler, and C.A. Stratakis Clinical and molecular genetics of Carney complex Best Pract Res Clin Endocrinol Metab 24 2010 389 399
20. J. Bertherat, L. Groussin, F. Sandrini, L. Matyakhina, T. Bei, S. Stergiopoulos, T. Papageorgiou, I. Bourdeau, L.S. Kirschner, and C. Vincent-Dejean Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity Cancer Res 63 2003 5308 5319 (Pubitemid 37139845)
21. A. Horvath, S. Boikos, C. Giatzakis, A. Robinson-White, L. Groussin, K.J. Griffin, E. Stein, E. Levine, G. Delimpasi, and H.P. Hsiao A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia Nat Genet 38 2006 794 800 (Pubitemid 43980600)
22. A. Horvath, C. Giatzakis, A. Robinson-White, S. Boikos, E. Levine, K. Griffin, E. Stein, V. Kamvissi, P. Soni, and I. Bossis Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population Cancer Res 66 2006 11571 11575 (Pubitemid 46094164)
23. R. Libé, A. Fratticci, J. Coste, F. Tissier, A. Horvath, B. Ragazzon, F. Rene-Corail, L. Groussin, X. Bertagna, and M.L. Raffin-Sanson Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors Clin Cancer Res 14 2008 4016 4024
24. R. Libé, A. Horvath, D. Vezzosi, A. Fratticci, J. Coste, K. Perlemoine, B. Ragazzon, M. Guillaud-Bataille, L. Groussin, and E. Clauser Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype J Clin Endocrinol Metab 96 2011 E208 E214
25. F.R. Faucz, A. Horvath, A. Rothenbuhler, M.Q. Almeida, R. Libé, M.L. Raffin-Sanson, J. Bertherat, D.M. Carraro, F.A. Soares, and C. Molina Gde Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer J Clin Endocrinol Metab 96 2011 E135 E140
26. A. Horvath, V. Mericq, and C.A. Stratakis Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase in adrenal hyperplasia N Engl J Med 358 2008 750 752 (Pubitemid 351240774)
27. A. Rothenbuhler, A. Horvath, F. Faucz, M. Almeida, M. Lodish, R. Libe, M. Nesterova, J. Bertherat, and C.A. Stratakis Three novel mutations in PDE8B, a cAMP phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumors Program of the 91st Annual Meeting of the Endocrine Society Washington, DC 2009
28. A. Horvath, C. Giatzakis, K. Tsang, E. Greene, P. Osorio, S. Boikos, R. Libe, Y. Patronas, A. Robinson-White, and E. Remmers A cAMP-specific phosphodiesterase (PDE8B) that is mutated in adrenal hyperplasia is expressed widely in human and mouse tissues: a novel PDE8B isoform in human adrenal cortex Eur J Hum Genet 16 2008 1245 1253
29. L.C. Tsai, M. Shimizu-Albergine, and J.A. Beavo The high-affinity cAMP-specific phosphodiesterase 8B controls steroidogenesis in the mouse adrenal gland Mol Pharmacol 79 2011 639 648
30. E.I. Bimpaki, M. Nesterova, and C.A. Stratakis Abnormalities of cAMP signaling are present in adrenocortical lesions associated with ACTH-independent Cushing syndrome despite the absence of mutations in known genes Eur J Endocrinol 161 2009 153 161
31. M. Hayashi, K. Matsushima, H. Ohashi, H. Tsunoda, S. Murase, Y. Kawarada, and T. Tanaka Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3′,5′-cyclic nucleotide phosphodiesterase Biochem Biophys Res Commun 250 1998 751 756 (Pubitemid 28484799)
32. L. Arnaud-Lopez, G. Usala, G. Ceresini, B.D. Mitchell, M.G. Pilia, M.G. Piras, N. Sestu, A. Maschio, F. Busonero, and G. Albai Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function Am J Hum Genet 82 2008 1270 1280
33. C.B. Volpato, A. De Grandi, M. Gögele, D. Taliun, C. Fuchsberger, M.F. Facheris, C. Minelli, C. Pattaro, P.P. Pramstaller, and A.A. Hicks Linkage and association analysis of hyperthyrotropinaemia in an Alpine population reveal two novel loci on chromosomes 3q28-29 and 6q26-27 J Med Genet 48 2011 549 556
34. A. Lania, L. Persani, E. Ballaré, S. Mantovani, M. Losa, and A. Spada Constitutively active Gs alpha is associated with an increased phosphodiesterase activity in human growth hormone-secreting adenomas J Clin Endocrinol Metab 83 1998 1624 1628 (Pubitemid 28501033)
35. X. Jiang, M. Paskind, R. Weltzien, and P.M. Epstein Expression and regulation of mRNA for distinct isoforms of cAMP-specific PDE-4 in mitogen-stimulated and leukemic human lymphocytes Cell Biochem Biophys 28 1998 135 160 (Pubitemid 128533774)
36. C. Lugnier Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents Pharmacol Ther 109 2006 366 398 (Pubitemid 43132818)
37. K. Shimizu, T. Murata, Y. Watanabe, C. Sato, H. Morita, and T. Tagawa Characterization of phosphodiesterase 1 in human malignant melanoma cell lines Anticancer Res 29 2009 1119 1122
38. F.G. Boess, M. Hendrix, F.J. van der Staay, C. Erb, R. Schreiber, W. van Staveren, J. de Vente, J. Prickaerts, A. Blokland, and G. Koenig Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance Neuropharmacology 47 2004 1081 1092 (Pubitemid 39535847)
39. K. Domek-Łopacińska, and J.B. Strosznajder The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging Brain Res 1216 2008 68 77
40. L. Favot, T. Keravis, V. Holl, A. Le Bec, and C. Lugnier VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors Thromb Haemost 90 2003 334 343 (Pubitemid 36992510)
41. J. Wenzel, R. Zeisig, and I. Fichtner Inhibition of metastasis in a murine 4T1 breast cancer model by liposomes preventing tumor cell-platelet interactions Clin Exp Metastasis 27 2010 25 34
42. K. Murata, M. Kameyama, F. Fukui, H. Ohigashi, M. Hiratsuka, Y. Sasaki, T. Kabuto, M. Mukai, T. Mammoto, and H. Akedo Phosphodiesterase type III inhibitor, cilostazol, inhibits colon cancer cell motility Clin Exp Metastasis 17 1999 525 530 (Pubitemid 30182747)
43. D. Bobon, M. Breulet, M.A. Gerard-Vandenhove, F. Guiot-Goffioul, G. Plomteux, M. Sastre-y-Hernández, M. Schratzer, B. Troisfontaines, R. von Frenckell, and H. Wachtel Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives Eur Arch Psychiatry Neurol Sci 238 1988 2 6 (Pubitemid 19008259)
44. P. Goldhoff, N.M. Warrington, D.D. Limbrick Jr. , A. Hope, B.M. Woerner, E. Jackson, A. Perry, D. Piwnica-Worms, and J.B. Rubin Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression Clin Cancer Res 14 2008 7717 7725
45. E. Kolosionek, R. Savai, H.A. Ghofrani, N. Weissmann, A. Guenther, F. Grimminger, W. Seeger, G.A. Banat, R.T. Schermuly, and S.S. Pullamsetti Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4 Mol Biol Cell 20 2009 4751 4765
46. D.H. Kim, and A. Lerner Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia Blood 92 1998 2484 2494 (Pubitemid 28452992)
47. A. Lerner, D.H. Kim, and R. Lee The cAMP signaling pathway as a therapeutic target in lymphoid malignancies Leuk Lymphoma 37 2000 39 51 Review (Pubitemid 30142578)
48. W.J. Thompson, G.A. Piazza, H. Li, L. Liu, J. Fetter, B. Zhu, G. Sperl, D. Ahnen, and R. Pamukcu Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphatephosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin Cancer Res 60 2000 3338 3342 (Pubitemid 30482142)
49. G.A. Piazza, W.J. Thompson, R. Pamukcu, H.W. Alila, C.M. Whitehead, L. Liu, J.R. Fetter, W.E. Gresh Jr. , A.J. Klein-Szanto, and D.R. Farnell Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis Cancer Res 61 2001 3961 3968 (Pubitemid 32720958)
50. V. Boswell-Smith, D. Spina, and C.P. Page Phosphodiesterase inhibitors Br J Pharmacol 147 Suppl. 1 2006 S252 S257
51. I. Arozarena, B. Sanchez-Laorden, L. Packer, C. Hidalgo-Carcedo, R. Hayward, A. Viros, E. Sahai, and R. Marais Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A Cancer Cell 19 2011 45 57
52. E. Bischoff Potency, selectivity, and consequences of nonselectivity of PDE inhibition Int J Impot Res Suppl. 1 2004 S11 S14
53. N.M. Kerr, and H.V. Danesh-Meyer Phosphodiesterase inhibitors and the eye Clin Experiment Ophthalmol 37 2009 514 523
54. C. Wayman, S. Phillips, C. Lunny, T. Webb, L. Fawcett, R. Baxendale, and G. Burgess Phosphodiesterase 11 (PDE11) regulation of spermatozoa physiology Int J Impot Res 17 2005 216 223 (Pubitemid 40675501)
55. K. Loughney, J. Taylor, and V.A. Florio 3′,5′-Cyclic nucleotide phosphodiesterase 11A: localization in human tissues Int J Impot Res 17 2005 320 325 (Pubitemid 41025763)
56. S.H. Francis Phosphodiesterase 11 (PDE11): is it a player in human testicular function? Int J Impot Res 17 2005 467 468 (Pubitemid 43093252)
57. L. Fawcett, R. Baxendale, P. Stacey, C. McGrouther, I. Harrow, S. Soderling, J. Hetman, J.A. Beavo, and S.C. Phillips Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A Proc Natl Acad Sci U S A 97 2000 3702 3707 (Pubitemid 30183366)
58. M.R. D'Andrea, Y. Qiu, D. Haynes-Johnson, S. Bhattacharjee, P. Kraft, and S. Lundeen Expression of PDE11A in normal and malignant human tissues J Histochem Cytochem 53 2005 895 903 (Pubitemid 40923465)
59. S.A. Boikos, A. Horvath, S. Heyerdahl, E. Stein, A. Robinson-White, I. Bossis, J. Bertherat, J.A. Carney, and C.A. Stratakis Phosphodiesterase 11A expression in the adrenal cortex, primary pigmented nodular adrenocortical disease, and other corticotropin-independent lesions Horm Metab Res 40 2008 347 353 (Pubitemid 351859447)
60. P. Serafini, K. Meckel, M. Kelso, K. Noonan, J. Califano, W. Koch, L. Dolcetti, V. Bronte, and I. Borrello Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function J Exp Med 203 2006 2691 2702 (Pubitemid 44833345)
61. M. Sarfati, V. Mateo, S. Baudet, M. Rubio, C. Fernandez, F. Davi, J.L. Binet, J. Delic, and H. Merle-Beral Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells Blood 101 2003 265 269 (Pubitemid 36025917)
62. H.N. Tinsley, B.D. Gary, A.B. Keeton, W. Zhang, A.H. Abadi, R.C. Reynolds, and G.A. Piazza Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G Mol Cancer Ther 8 2009 3331 3340
63. C.M. Whitehead, K.A. Earle, J. Fetter, S. Xu, T. Hartman, D.C. Chan, T.L. Zhao, G. Piazza, A.J. Klein-Szanto, and R. Pamukcu Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival Mol Cancer Ther 2 2003 479 488
64. B. Zhu, L. Vemavarapu, W.J. Thompson, and S.J. Strada Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells J Cell Biochem 94 2005 336 350 (Pubitemid 41420312)
65. H. Tinel, B. Stelte-Ludwig, J. Hütter, and P. Sandner Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms BJU Int 98 2006 1259 1263 (Pubitemid 44721238)
66. M. Hotston, N. Shukla, J. Bloor, R. Persad, and J.Y. Jeremy Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms BJU Int 98 2006 1331 1332 (Pubitemid 44721256)
67. V. Koika, Z. Zhou, I. Vasileiadis, C. Roussos, F. Finetti, M. Monti, L. Morbidelli, and A. Papapetropoulos PKG-I inhibition attenuates vascular endothelial growth factor-stimulated angiogenesis Vascul Pharmacol 53 2010 215 222
68. A. Pyriochou, Z. Zhou, V. Koika, C. Petrou, P. Cordopatis, W.C. Sessa, and A. Papapetropoulos The phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway J Cell Physiol 211 2007 197 204 (Pubitemid 46363910)
69. O.W. Griffith, and D.J. Stuehr Nitric oxide synthases: properties and catalytic mechanism Annu Rev Physiol 57 1995 707 736
70. Z. Zhao, C.E. Francis, G. Welch, J. Loscalzo, and K. Ravid Reduced glutathione prevents nitric oxide-induced apoptosis in vascular smooth muscle cells Biochim Biophys Acta 1359 1997 143 152 (Pubitemid 27507816)
71. R.F. Fauzc, R.B. de Alexandre, and C.A. Stratakis Phosphodiesterases: genes and their variants, inhibitors and potential therapeutic applications Expert Rev Endocrinol Metab 6 2011 497 499
72. L. Zhang, F. Murray, A. Zahno, J.R. Kanter, D. Chou, R. Suda, M. Fenlon, L. Rassenti, H. Cottam, T.J. Kipps, and P.A. Insel Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia Proc Natl Acad Sci U S A 105 2008 19532 19537
73. A.G. Vang, S.Z. Ben-Sasson, H. Dong, B. Kream, M.P. DeNinno, M.M. Claffey, W. Housley, R.B. Clark, P.M. Epstein, and S. Brocke PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER PLoS One 5 2010 e12011
74. J.L. Bos Epac proteins: multi-purpose cAMP targets Trends Biochem Sci 31 2006 680 686 (Pubitemid 44791945)
75. M. Kaneko, and T. Takahashi Presynaptic mechanism underlying cAMP-dependent synaptic potentiation J Neurosci 24 2004 5202 5208 (Pubitemid 38725403)
76. T. Sakaba, and E. Neher Direct modulation of synaptic vesicle priming by GABA(B) receptor activation at a glutamatergic synapse Nature 424 2003 775 778 (Pubitemid 37021706)
77. N. Zhong, and R.S. Zucker cAMP acts on exchange protein activated by cAMP/cAMP regulated guanine nucleotide exchange protein to regulate transmitter release at the crayfish neuromuscular junction J Neurosci 25 2005 208 214 (Pubitemid 40110782)
78. T.M. Lincoln, N. Dey, and H. Sellak Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression J Appl Physiol 91 2001 1421 1430 (Pubitemid 32803941)
79. L. Lefivre, E. de Lamirande, and C. Gagnon Presence of cyclic nucleotide phosphodiesterases PDE1A, existing as a stable complex with calmodulin, and PDE3A in human spermatozoa Biol Reprod 67 2002 423 430 (Pubitemid 34803924)
80. M. Fidock, M. Miller, and J. Lanfear Isolation and differential tissue distribution of two human cDNAs encoding PDE1 splice variants Cell Signal 14 2002 53 60 (Pubitemid 34020829)
81. 2+/calmodulin-dependent phosphodiesterase PDE1A: novel splice variants, their specific expression, genomic organization, and chromosomal localization Biochim Biophys Acta 1517 2001 278 287 (Pubitemid 32126526)
82. K. Loughney, T.J. Martins, E.A. Harris, K. Sadhu, J.B. Hicks, W.K. Sonnenburg, J.A. Beavo, and K. Ferguson Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3′,5′- cyclic nucleotide phosphodiesterases J Biol Chem 271 1996 796 806
83. N. Kanda, and S. Watanabe Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells Biochem Pharmacol 62 2001 495 507 (Pubitemid 32607733)
84. C. Yan, A.Z. Zhao, J.K. Bentley, K. Loughney, K. Ferguson, and J.A. Beavo Molecular cloning and characterization of a calmodulin-dependent phosphodiesterase enriched in olfactory sensory neurons Proc Natl Acad Sci U S A 92 1995 9677 9681
85. V.O. Nikolaev, S. Gambaryan, S. Engelhardt, U. Walter, and M.J. Lohse Real-time monitoring of the PDE2 activity of live cells: hormone-stimulated cAMP hydrolysis is faster than hormone-stimulated cAMP synthesis J Biol Chem 280 2005 1716 1719
86. M. Mongillo, C.G. Tocchetti, A. Terrin, V. Lissandron, Y.F. Cheung, W.R. Dostmann, T. Pozzan, D.A. Kass, N. Paolocci, and M.D. Houslay Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway Circ Res 98 2006 226 234
87. A.T. Bender, C.L. Ostenson, D. Giordano, and J.A. Beavo Differentiation of human monocytes in vitro with granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor produces distinct changes in cGMP phosphodiesterase expression Cell Signal 16 2004 365 374 (Pubitemid 37542411)
88. J. Seybold, D. Thomas, M. Witzenrath, S. Boral, A.C. Hocke, A. Bürger, A. Hatzelmann, H. Tenor, C. Schudt, and M. Krüll Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability Blood 105 2005 3569 3576 (Pubitemid 40628202)
89. S.K. de Oliveira, and A. Smolenski Phosphodiesterases link the aryl hydrocarbon receptor complex to cyclic nucleotide signaling Biochem Pharmacol 77 2009 723 733
90. D.H. Maurice, D. Palmer, D.G. Tilley, H.A. Dunkerley, S.J. Netherton, D.R. Raymond, H.S. Elbatarny, and S.L. Jimmo Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system Mol Pharmacol 64 2003 533 546 (Pubitemid 37048555)
91. E. Degerman, P. Belfrage, and V.C. Manganiello Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3) J Biol Chem 272 1997 6823 6826 (Pubitemid 27166373)
92. G. Rena, F. Begg, A. Ross, C. MacKenzie, I. McPhee, L. Campbell, E. Huston, M. Sullivan, and M.D. Houslay Molecular cloning, genomic positioning, promoter identification, and characterization of the novel cyclic amp-specific phosphodiesterase PDE4A10 Mol Pharmacol 59 2001 996 1011 (Pubitemid 32381578)
93. P. Wang, P. Wu, K.M. Ohleth, R.W. Egan, and M.M. Billah Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils Mol Pharmacol 56 1999 170 174 (Pubitemid 29309826)
94. G. Bolger, T. Michaeli, T. Martins, T. St John, B. Steiner, L. Rodgers, M. Riggs, M. Wigler, and K. Ferguson A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs Mol Cell Biol 13 1993 6558 6571 (Pubitemid 23292650)
95. T.R. Dunkern, and A. Hatzelmann The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5 Cell Signal 17 2005 331 339 (Pubitemid 39574694)
96. J. Prickaerts, A. Sik, W.C. van Staveren, G. Koopmans, H.W. Steinbusch, F.J. van der Staay, J. de Vente, and A. Blokland Phosphodiesterase type 5 inhibition improves early memory consolidation of object information Neurochem Int 45 2004 915 928 (Pubitemid 39108064)
97. C.L. Miller, and C. Yan Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications J Cardiovasc Transl Res 3 2010 507 515
98. K.D. Ridge, N.G. Abdulaev, M. Sousa, and K. Palczewski Phototransduction: crystal clear Trends Biochem Sci 28 2003 479 487 (Pubitemid 38340412)
99. F. Morin, C. Lugnier, J. Kameni, and P. Voisin Expression and role of phosphodiesterase 6 in the chicken pineal gland J Neurochem 78 2001 88 99 (Pubitemid 32622591)
100. T.J. Bloom, and J.A. Beavo Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants Proc Natl Acad Sci U S A 93 1996 14188 14192 (Pubitemid 26424267)
101. P. Han, X. Zhu, and T. Michaeli Alternative splicing of the high affinity cAMP specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart J Biol Chem 272 1997 16152 16157 (Pubitemid 27276430)
102. T. Sasaki, J. Kotera, and K. Omori Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP dependent protein kinase/cyclic AMP-response element binding protein pathway in primary striatal neurons J Neurochem 89 2004 474 483 (Pubitemid 38495995)
103. N.A. Glavas, C. Ostenson, J.B. Schaefer, V. Vasta, and Beavo T cell activation upregulates cyclic nucleotide phosphodiesterases 8A1 and 7A3 Proc Natl Acad Sci U S A 98 2001 6319 6324 (Pubitemid 32488237)
104. E. Patrucco, M.S. Albergine, L.F. Santana, and J.A. Beavo Phosphodiesterase 8A (PDE8A) regulates excitation-contraction coupling in ventricular myocytes J Mol Cell Cardiol 49 2010 330 333
105. C. Mehats, C.B. Andersen, M. Filopanti, S.L. Jin, and M. Conti Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling Trends Endocrinol Metab 13 2002 29 35 (Pubitemid 36734013)
106. M. Hayashi, Y. Shimada, Y. Nishimura, T. Hama, and T. Tanaka Genomic organization, chromosomal localization, and alternative splicing of the human phosphodiesterase 8B gene Biochem Biophys Res Commun 297 2002 1253 1258 (Pubitemid 35221349)
107. C. Rentero, A. Monfort, and P. Puigdomenech Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene Biochem Biophys Res Commun 301 2003 686 692 (Pubitemid 36268946)
108. S.G. Andreeva, P. Dikkes, P.M. Epstein, and P.A. Rosenberg Expression of cGMP specific phosphodiesterase 9A mRNA in the rat brain J Neurosci 21 2001 9068 9076 (Pubitemid 33054868)
109. K. Fujishige, J. Kotera, H. Michibata, K. Yuasa, S. Takebayashi, K. Okumura, and K. Omori Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A) J Biol Chem 274 1999 18438 18445
110. K. Yuasa, J. Kotera, K. Fujishige, H. Michibata, T. Sasaki, and K. Omori Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression J Biol Chem 275 2000 31469 31479